Article Text

Download PDFPDF
2SPD-006 Analysis of rituximab off-label use in a tertiary hospital
  1. ME Cárdaba García,
  2. S Fernández Peña,
  3. M Izquierdo Navarro,
  4. S Izquierdo Muñoz,
  5. MT Sánchez Sánchez
  1. Hospital Clínico Universitario, Hospital Pharmacy, Valladolid, Spain


Background The implementing Law 1015/2009 normalises the compassionate use of investigational drugs, access to off-label and unauthorised drugs in Spain.

Rituximab is an anti-CD20 monoclonal antibody widely used in off-label conditions to treat autoimmune diseases.1,2,3,4

Purpose The creation of an Autoimmune Diseases Unit (ADU) in our hospital caused an increase in the use of rituximab in off-label conditions. This study aims to identify rituximab off-label use and to describe the dosage prescribed in each indication.

Material and methods Observational, retrospective study (June 2009 to March 2017). Patients who received off-label rituximab (at least one dose) prescribed by the ADU were included.

Collected data, obtained from Farmatools® software and medical records, were: sex, age, rituximab off-label indication, dosage, number of cycles received.

Results Forty-four patients (55±15 years’ old, 31/44 females) received off-label rituximab.

Off-label indications identified (all of them of autoimmune aetiology) were: systemic lupus erythematosus (16/44), vasculitis (13/44), inflammatory myopathy (6/44), scleroderma (4/44), mixed cryoglobulinemia (3/44), others (2/44).

The rituximab prescribed regimen was a cycle consisting of four doses of 375 mg/m2 administered weekly, which is the dosage aprobed for the treatment of lymphoma. 23/44 patients received a single cycle of treatment with rituximab, 11/44 received two cycles, 2/44 received three cycles and 2/44 more than four cycles, which is partially consistent with the literature previously published1,2,3,4 (most patients received one cycle). 6/44 patients did nott start rituximab treatment.

Conclusion Systemic lupus erythematosus and vasculitis were the most frequently rituximab off-label prescribed indications and 375 mg/m2 weekly for 4 weeks was the prescribed dosage. These results agree with the data published in the literature.1,2,3,4

Considering the variety of off-label indications for which rituximab is prescribed in the ADU, it would be useful to develop protocols for the use of rituximab in these situations.

References and/or Acknowledgements 1. Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Reumathol2010;29(7):707–716.

2. Hiemstra T, Jayne D. Newer therapies for vasculitis. Best Pract Res Clin Rheumatol2009;23(3):379–389.

3. Daoussis D, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology2010;49:271–280.

4. Saunders P, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated intersticial luna disease (RECITAL): Study protocol for a randomised controlled trial. Trials2017;18(1):27.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.